世界のゲノムベース薬市場予測（～2028年）：インスリン、成長ホルモン、モノクローナル抗体、その他

• 英文タイトル：Global Genome-Based Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

• レポートコード：GIR-22E8832 • 出版社/出版日：GlobalInfoResearch / 2022年5月 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

ゲノムベース薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界のゲノムベース薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 ゲノムベース薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・インスリン、成長ホルモン、モノクローナル抗体、その他 用途別セグメントは次のように区分されます。 ・病院、製薬工場、その他 世界のゲノムベース薬市場の主要な市場プレーヤーは以下のとおりです。 ・Sandoz International、Teva pharmaceutical industries、Mylan、3SBio、Shanghai Fosun Pharmaceutical、Tonghua Dongbao Pharmaceutical、Biocon、Reliance Life Sciences、Probiomed、Biosidus、AMEGA Biotech、Celltrion、LG Life Science、Dong-A Pharmaceutical 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、ゲノムベース薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なゲノムベース薬メーカーの企業概要、2019年～2022年までのゲノムベース薬の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なゲノムベース薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別ゲノムベース薬の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までのゲノムベース薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのゲノムベース薬市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、およびゲノムベース薬の産業チェーンを掲載しています。 ・第13、14、15章では、ゲノムベース薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Sandoz International、Teva pharmaceutical industries、Mylan、3SBio、Shanghai Fosun Pharmaceutical、Tonghua Dongbao Pharmaceutical、Biocon、Reliance Life Sciences、Probiomed、Biosidus、AMEGA Biotech、Celltrion、LG Life Science、Dong-A Pharmaceutical ・メーカー別市場シェア ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：インスリン、成長ホルモン、モノクローナル抗体、その他 ・用途別分析2017年-2028年：病院、製薬工場、その他 ・ゲノムベース薬の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ ・ゲノムベース薬のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア ・ゲノムベース薬のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア ・ゲノムベース薬の南米市場規模2017年-2028年：ブラジル、アルゼンチン ・ゲノムベース薬の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Genome-Based Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Genome-Based Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Genome-Based Drug global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Insulin segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Genome-Based Drug include Sandoz International, Teva pharmaceutical industries, Mylan, 3SBio, and Shanghai Fosun Pharmaceutical, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Genome-Based Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Insulin
Growth Hormone
Monoclonal Antibody
Other
Market segment by Application can be divided into
Hospital
Pharmaceutical Factory
Other
The key market players for global Genome-Based Drug market are listed below:
Sandoz International
Teva pharmaceutical industries
Mylan
3SBio
Shanghai Fosun Pharmaceutical
Tonghua Dongbao Pharmaceutical
Biocon
Reliance Life Sciences
Probiomed
Biosidus
AMEGA Biotech
Celltrion
LG Life Science
Dong-A Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Genome-Based Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Genome-Based Drug, with price, sales, revenue and global market share of Genome-Based Drug from 2019 to 2022.
Chapter 3, the Genome-Based Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Genome-Based Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Genome-Based Drug market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Genome-Based Drug.
Chapter 13, 14, and 15, to describe Genome-Based Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Genome-Based Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Genome-Based Drug Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Insulin
1.2.3 Growth Hormone
1.2.4 Monoclonal Antibody
1.2.5 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Genome-Based Drug Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Pharmaceutical Factory
1.3.4 Other
1.4 Global Genome-Based Drug Market Size & Forecast
1.4.1 Global Genome-Based Drug Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Genome-Based Drug Sales in Volume (2017-2028)
1.4.3 Global Genome-Based Drug Price (2017-2028)
1.5 Global Genome-Based Drug Production Capacity Analysis
1.5.1 Global Genome-Based Drug Total Production Capacity (2017-2028)
1.5.2 Global Genome-Based Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Genome-Based Drug Market Drivers
1.6.2 Genome-Based Drug Market Restraints
1.6.3 Genome-Based Drug Trends Analysis
2 Manufacturers Profiles
2.1 Sandoz International
2.1.1 Sandoz International Details
2.1.2 Sandoz International Major Business
2.1.3 Sandoz International Genome-Based Drug Product and Services
2.1.4 Sandoz International Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Teva pharmaceutical industries
2.2.1 Teva pharmaceutical industries Details
2.2.2 Teva pharmaceutical industries Major Business
2.2.3 Teva pharmaceutical industries Genome-Based Drug Product and Services
2.2.4 Teva pharmaceutical industries Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Mylan
2.3.1 Mylan Details
2.3.2 Mylan Major Business
2.3.3 Mylan Genome-Based Drug Product and Services
2.3.4 Mylan Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 3SBio
2.4.1 3SBio Details
2.4.2 3SBio Major Business
2.4.3 3SBio Genome-Based Drug Product and Services
2.4.4 3SBio Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Shanghai Fosun Pharmaceutical
2.5.1 Shanghai Fosun Pharmaceutical Details
2.5.2 Shanghai Fosun Pharmaceutical Major Business
2.5.3 Shanghai Fosun Pharmaceutical Genome-Based Drug Product and Services
2.5.4 Shanghai Fosun Pharmaceutical Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Tonghua Dongbao Pharmaceutical
2.6.1 Tonghua Dongbao Pharmaceutical Details
2.6.2 Tonghua Dongbao Pharmaceutical Major Business
2.6.3 Tonghua Dongbao Pharmaceutical Genome-Based Drug Product and Services
2.6.4 Tonghua Dongbao Pharmaceutical Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Biocon
2.7.1 Biocon Details
2.7.2 Biocon Major Business
2.7.3 Biocon Genome-Based Drug Product and Services
2.7.4 Biocon Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Reliance Life Sciences
2.8.1 Reliance Life Sciences Details
2.8.2 Reliance Life Sciences Major Business
2.8.3 Reliance Life Sciences Genome-Based Drug Product and Services
2.8.4 Reliance Life Sciences Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Probiomed
2.9.1 Probiomed Details
2.9.2 Probiomed Major Business
2.9.3 Probiomed Genome-Based Drug Product and Services
2.9.4 Probiomed Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Biosidus
2.10.1 Biosidus Details
2.10.2 Biosidus Major Business
2.10.3 Biosidus Genome-Based Drug Product and Services
2.10.4 Biosidus Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 AMEGA Biotech
2.11.1 AMEGA Biotech Details
2.11.2 AMEGA Biotech Major Business
2.11.3 AMEGA Biotech Genome-Based Drug Product and Services
2.11.4 AMEGA Biotech Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Celltrion
2.12.1 Celltrion Details
2.12.2 Celltrion Major Business
2.12.3 Celltrion Genome-Based Drug Product and Services
2.12.4 Celltrion Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 LG Life Science
2.13.1 LG Life Science Details
2.13.2 LG Life Science Major Business
2.13.3 LG Life Science Genome-Based Drug Product and Services
2.13.4 LG Life Science Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Dong-A Pharmaceutical
2.14.1 Dong-A Pharmaceutical Details
2.14.2 Dong-A Pharmaceutical Major Business
2.14.3 Dong-A Pharmaceutical Genome-Based Drug Product and Services
2.14.4 Dong-A Pharmaceutical Genome-Based Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Genome-Based Drug Breakdown Data by Manufacturer
3.1 Global Genome-Based Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Genome-Based Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Genome-Based Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Genome-Based Drug Manufacturer Market Share in 2021
3.4.2 Top 6 Genome-Based Drug Manufacturer Market Share in 2021
3.5 Global Genome-Based Drug Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Genome-Based Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Genome-Based Drug Market Size by Region
4.1.1 Global Genome-Based Drug Sales in Volume by Region (2017-2028)
4.1.2 Global Genome-Based Drug Revenue by Region (2017-2028)
4.2 North America Genome-Based Drug Revenue (2017-2028)
4.3 Europe Genome-Based Drug Revenue (2017-2028)
4.4 Asia-Pacific Genome-Based Drug Revenue (2017-2028)
4.5 South America Genome-Based Drug Revenue (2017-2028)
4.6 Middle East and Africa Genome-Based Drug Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Genome-Based Drug Sales in Volume by Type (2017-2028)
5.2 Global Genome-Based Drug Revenue by Type (2017-2028)
5.3 Global Genome-Based Drug Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Genome-Based Drug Sales in Volume by Application (2017-2028)
6.2 Global Genome-Based Drug Revenue by Application (2017-2028)
6.3 Global Genome-Based Drug Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Genome-Based Drug Sales by Type (2017-2028)
7.2 North America Genome-Based Drug Sales by Application (2017-2028)
7.3 North America Genome-Based Drug Market Size by Country
7.3.1 North America Genome-Based Drug Sales in Volume by Country (2017-2028)
7.3.2 North America Genome-Based Drug Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Genome-Based Drug Sales by Type (2017-2028)
8.2 Europe Genome-Based Drug Sales by Application (2017-2028)
8.3 Europe Genome-Based Drug Market Size by Country
8.3.1 Europe Genome-Based Drug Sales in Volume by Country (2017-2028)
8.3.2 Europe Genome-Based Drug Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Genome-Based Drug Sales by Type (2017-2028)
9.2 Asia-Pacific Genome-Based Drug Sales by Application (2017-2028)
9.3 Asia-Pacific Genome-Based Drug Market Size by Region
9.3.1 Asia-Pacific Genome-Based Drug Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Genome-Based Drug Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Genome-Based Drug Sales by Type (2017-2028)
10.2 South America Genome-Based Drug Sales by Application (2017-2028)
10.3 South America Genome-Based Drug Market Size by Country
10.3.1 South America Genome-Based Drug Sales in Volume by Country (2017-2028)
10.3.2 South America Genome-Based Drug Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Genome-Based Drug Sales by Type (2017-2028)
11.2 Middle East & Africa Genome-Based Drug Sales by Application (2017-2028)
11.3 Middle East & Africa Genome-Based Drug Market Size by Country
11.3.1 Middle East & Africa Genome-Based Drug Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Genome-Based Drug Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Genome-Based Drug and Key Manufacturers
12.2 Manufacturing Costs Percentage of Genome-Based Drug
12.3 Genome-Based Drug Production Process
12.4 Genome-Based Drug Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Genome-Based Drug Typical Distributors
13.3 Genome-Based Drug Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

---